Browse drugs

…index of IL-2 by maintaining the superior potency attributed to Aldesleukin treatment without compromising on the improved safety (as measu…

… been approved for human use: FLyP, LyoPlas, Bioplasma FDP, and OctaplasLG Powder. All of these are freeze-dried in glass bottles and produced by…

…oprine proved ineffective in maintaining clinical remission and Infliximab was initiated. Due to ongoing symptoms her IFX dose was increas…

…denser, compact cells in the NEC+ pups (p<0.0001, n=320 cells). HB-EGF+/NEC+ and HB-EGF–/NEC+ pups had similar-appearing microglia.Con…

…Vedolizumab and Ustekinumab were first approved by our trust for treatment of patients with…

…l lung cancer (ES-SCLC) provides only modest survival benefits. Tislelizumab has been recently approved by the European Commission, but head…

…d due to lack of efficacy. Tolerability was generally good. For atogepant, six patients stopped due to adverse events, most commonly fati…

…underwent sequential treatment with lamotrigine, valproic acid, vigabatrin, levetiracetam, primidone, ketogenic diet, rufinamide, topirama…

…izumab had higher AE incidence without additional efficacy over pembrolizumab alone. Safety results were overall consistent with the known sa…

… reduction in NK and B cells. When 177Lu-PSMA was combined with pembrolizumab, we saw dynamic changes in non-Treg T cell subsets (CD4+ and CD…

…%) normalised within 6 months as compared to 18/28 (64.3%) with fenofibrate. This was not significantly different between the groups (p=0.4…

…an cardiac microvascular endothelial cells (HCMEC) treated with TNFα (2ng/ml), 17-HDHA restored peripheral cytoplasmic integrity by …